Skip to main content
Log in

Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C

  • Articles
  • Published:
Medical Oncology and Tumor Pharmacotherapy Aims and scope Submit manuscript

Abstract

Forty-six patients with recurrent metastatic breast cancer were treated with a combination chemotherapy including doxorubicin and mitomycin C. Myocardial contractility was monitored by means of echocardiography. During therapy there was a progressive deterioration of myocardial function, and this phenomenon was found to be linearly correlated to the cumulative dose of doxorubicin. Six patients (13.8%) developed congestive heart failure during therapy; it occurred after the median cumulative dose of 322 mg/m2 (range 135–472). Possible risk factors of cardiomyopathy could be identified in only two patients. These results suggest that mitomycin C could enhance the cardiotoxicity of doxorubicin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blum R H, Carter S K: Adriamycin: a new anticancer drug with significant clinical activity.Ann Intern Med 80, 249 (1974).

    PubMed  CAS  Google Scholar 

  2. Ugoretz R F: Cardiac effects of doxorubicin therapy of neoplasms.J Am Med Assoc 236, 295 (1976).

    Article  CAS  Google Scholar 

  3. Bristow M R, Mason J W, Billingham M E, Daniels J R: Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization.Ann Intern Med 88, 168 (1978).

    PubMed  CAS  Google Scholar 

  4. Von Hoff D D, Layard M W, Basa P, Davis H L Jr, Von Hoff A L, Rozencweig M, Muggia F M: Risk factors for doxorubicin-induced congestive heart failure.Ann Int Med 91, 710 (1979).

    Google Scholar 

  5. Kinsella T J, Ahmann D L, Giuliani E R, Lie J T: Adriamycin cardiotoxicity in stage IV breast cancer: possible enhancement with prior left chest radiation therapy.Int J Radiat Oncol Biol Phys 5, 1997 (1979).

    PubMed  CAS  Google Scholar 

  6. Minow R A, Benjamin R S, Lee E T, Gottlieb J A: Adriamycin cardiomyopathy: risk factors.Cancer 39, 1397 (1977).

    Article  PubMed  CAS  Google Scholar 

  7. Merrill J P, Greco F A, Zimbler H, Brereton H D, Lamberg J D, Pomeroy T C: Ariamycin and radiation synergistic cardiotoxicity.Ann Intern Med 82, 122 (1975).

    PubMed  CAS  Google Scholar 

  8. Praga C, Beratta G, Vigo P L, Lenan G R, Pollini C, Bonadonna G, Canetta R, Castellani R, Villa E, Gallagher C G, von Melchner H, Hayat M, Ribaud P, De Wasch G, Mattsson W, Heinz R, Waldner R, Kolaric K, Buehner R, Ten Bokkel-Huynink W, Perevodchikova N I, Manziuk L A, Senn H J, Mayr A C: Adriamycin cardiotoxicity: a survey of 1273 patients.Cancer Treat Rep 63, 827 (1979).

    PubMed  CAS  Google Scholar 

  9. Prout M N, Richards M J S, Chung K J, Joo P, Davis H L Jr: Adriamycin cardiotoxicity in children: case reports. literature review and risk factors.Cancer 39, 62 (1977).

    Article  PubMed  CAS  Google Scholar 

  10. Kushner J P, Hansen V L, Hammar S P: Cardiomyopathy after widely separated courses of adriamycin.Cancer 36, 1577 (1975).

    Article  PubMed  CAS  Google Scholar 

  11. Minow R A, Benjamin R S, Gottlieb J A: Adriamycin (NSC 123–127) cardiomyopathy: an overview with determination of risk factors.Cancer Chemother Rep 6, 195 (1975).

    Google Scholar 

  12. O’Connell T X, Berenbaum M C: Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide.Cancer Research 34, 1586 (1974).

    PubMed  CAS  Google Scholar 

  13. Bitran J D: Doxorubicin cardiotoxicity and melphalan.Ann Int med 95, 243 (1981).

    PubMed  CAS  Google Scholar 

  14. Buzdar A U, Legha S S, Tashima C K, Hortobagyi G N, Yong Yap H, Krutchik A N, Luna M A, Blumenschein G R: Adriamycin and mitomycin C: possible synergistic cardiotoxicity.Cancer Treat Rep 62, 1005 (1978).

    PubMed  CAS  Google Scholar 

  15. Jain K, Wittes R, Benedetto P, Kaufman R, Currie V, Hakes T, Bosl G: A randomized comparison of weekly (arm I) versus monthly (arm II) doxorubicin in combination with mitomycin C in advanced breast cancer (abstract).Proceedings ASCO, San Diego, May, p. 109 (1983).

  16. Creech R H, Dayal H, Catalano R B, Dierks K, Shah M K: Combination doxorubicin-mitomycin therapy for hormonal and CMF-refractory metastatic breast cancer (abstract).Proceeding ASCO, Toronto, May, p. 126 (1984).

  17. Knapp W H: Relationship between mean velocity of circumferential fiber shortening (VCF) and heart rate. The diagnostic value of a normalization of VCF heart rate.J Clin Ultrasound 6, 10 (1978).

    Article  PubMed  CAS  Google Scholar 

  18. Dinddogru A, Barcos M, Henderson E S, Wallace H J: Electrocardiographic changes following adriamycin treatment. Med Pediat Oncol5, 65 (1978).

    Article  Google Scholar 

  19. Villani F, Lacaita G, Genitoni V, Comazzi R, Guindani A: Comparative cardiotoxity of different anthracycline derivatives.Drugs Under Exp Clin Res 9, 781 (1983).

    Google Scholar 

  20. Villani F, Comazzi R, Lacaita G, Genitoni V, Guindani A, Martini A: Preliminary echocardiographic and polygraphic evaluation of cardiac toxicity of 4′-epi-doxorubicin.Int J Clin Pharmacol Ther Toxicol 21, 203 (1983).

    PubMed  CAS  Google Scholar 

  21. Bloom K R, Bini R M, Williams C M, Sonley M J, Gribbin M A: Echocardiography in adriamycin cardiotoxicity.Cancer 41, 1265 (1978).

    Article  PubMed  CAS  Google Scholar 

  22. Villani F, Beretta G, Guindani A, Pagnoni A, Vivarelli S: Valutazione policardiografica della cardiotossicità da adriamicina.G Ital Chemioter 22, 39 (1975).

    PubMed  CAS  Google Scholar 

  23. Rosi D R, Nogeire C, Brown B, Ali M, Ewer M, Samuels M: 5-Fluorouracil, adriamycin and mitomycin-C (H1-FAM) chemotherapy for adenocarcinoma of the lung.Cancer 48, 21 (1981).

    Article  PubMed  CAS  Google Scholar 

  24. Smith F P, Hoth D F, Levin B, Karlin D A, MacDonald J S, Wolley P V, Schein P S: 5-Fluorouracil, adriamycin and mitomycin-C (FAM). Chemotherapy for advanced adenocarcinoma of the pancreas.Cancer 46, 2014 (1980).

    Article  PubMed  CAS  Google Scholar 

  25. MacDonald J S, Schein P S, Wolley P V, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C: 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.Ann Int Med 93, 533 (1980).

    PubMed  CAS  Google Scholar 

  26. Lagothetis C J, von Eschenbach A C, Samuels M L, Trindade A, Johnson D E: Doxorubicin, mitomycin and 5-FU (DMF) in the treatment of hormone resistant stage D prostate cancer: a preliminary report.Cancer Treat Rep 66, 57 (1982).

    Google Scholar 

  27. Crooke S T, Bradner W T: Mitomycin C: a review.Cancer Treat Rep 3, 121 (1976).

    Article  CAS  Google Scholar 

  28. Philips F S, Schwartz H S, Sternberg S S: Pharmacology of mitomycin C.Cancer Res 20, 1354 (1960).

    PubMed  CAS  Google Scholar 

  29. Monti E, Bossa R, Galatulas I, Favalli L, Villani F, Piccinini F: Interaction between doxorubicin and mitomycin C on mortality and myocardial contractility in guinea pig.Tumori 69, 113 (1983).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Villani, F., Comazzi, R., Lacaita, G. et al. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med. Oncol. & Tumor Pharmacother. 2, 93–97 (1985). https://doi.org/10.1007/BF02934854

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02934854

Key words

Navigation